
European Journal of Medicinal Chemistry p. 789 - 797 (1998)
Update date:2022-07-29
Topics:
Dal Piaz, Vittorio
Giovannoni, Maria Paola
Castellana, Carla
Palacios, Jose Maria
Beleta, Jorge
Domenech, Teresa
Segarra, Victor
A novel group of heterocyclic-fused 3(2H)-pyridazinones were synthesized and evaluated as PDE III and PDE IV inhibitors and their affinity for 3H Rolipram high affinity binding site was determined. The obtained data demonstrated that some of the new compounds are endowed with potent and selective PDE IV inhibitory activity and greatly attenuated affinity for the Rolipram high affinity binding site that seems to be responsible for unwanted effects. Theoretical calculations, performed on representative compounds, demonstrated the presence of three hydrogen-bonding acceptor regions, of which one looks quite different with respect to literature compounds. This finding could explain the different pharmacological profile of the title compounds with respect to the analogs reported in the literature.
View MoreSuzhou Lixin Pharmaceutical Co., Ltd.
Contact:86-512-88169812
Address:21 Tangxi Road, Suzhou New District, Suzhou 215151
Shanghai Dano Pharmaceutical Co.,Ld.(expird)
Contact:+86-592-6266840
Address:Building 1 Room 512, 720 Cailun Rd, Zhangjiang High-Tech Park, Shanghai 201203, China
Contact:+86-0760-85282375
Address:zhongjing road,zhongshan torch hi-tech industrial development zone
Jiangxi Lanqi Fine Chemical S&T Co., Ltd.
Contact:+86-21-64891143
Address:XinJiShan Industrial Area, Zhangshu City, JiangXi Province, China
website:http://www.eastarchem.com/
Contact:1-800-898-2436
Address:1215 K Street, STE 1700
Doi:10.1021/ja00149a011
(1995)Doi:10.1016/j.tetlet.2014.03.004
(2014)Doi:10.1055/s-1994-25545
(1994)Doi:10.1016/j.tet.2014.03.037
(2014)Doi:10.1039/c4cc00857j
(2014)Doi:10.1016/j.molcata.2014.01.005
(2014)